Events

In this webinar, Lonza experts share insights from 70+ bispecific programs, revealing the most common early‑stage risks across analytical development, downstream purification, and drug product formulation. You’ll learn where challenges...

This webinar breaks down how evolving expectations under ICH Q5A(R2) are reshaping viral detection strategies, shifting the industry from targeted testing toward broader, more sensitive approaches. Through real‑world examples, you’ll...

IND submission is a critical milestone in mAb development — but analytical methods established at this stage must ultimately support validation, tech transfer, and evolving regulatory expectations. Among these, residual...

Explore how advanced nanoparticle engineering is transforming formulation across both small and large molecule modalities. Dr. Chris Worrall highlights how Nanoform’s technologies enable higher drug‑loading oral tablets, ultra‑high‑concentration biologic formulations...

In this session, leading cell therapy CDMOs will break down how they support programs across development—from early process work through GMP manufacturing, scale-up, and commercial readiness—and where different approaches can...

In this session, leading CDMO experts will break down the key decisions across host cell selection, vector design, and clone screening strategies, and explain how those choices impact expression, scalability,...